<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK2689" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK2689/" /><meta name="ncbi_pagename" content="MYH9-Related Disorders - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>MYH9-Related Disorders - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="MYH9-Related Disorders" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/07/16" /><meta name="citation_author" content="Anna Savoia" /><meta name="citation_author" content="Alessandro Pecci" /><meta name="citation_pmid" content="20301740" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK2689/" /><meta name="citation_keywords" content="May-Hegglin Anomaly" /><meta name="citation_keywords" content="Sebastian Syndrome" /><meta name="citation_keywords" content="Fechtner Syndrome" /><meta name="citation_keywords" content="Epstein Syndrome" /><meta name="citation_keywords" content="Myosin-9" /><meta name="citation_keywords" content="MYH9" /><meta name="citation_keywords" content="MYH9-Related Disorders" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="MYH9-Related Disorders" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Anna Savoia" /><meta name="DC.Contributor" content="Alessandro Pecci" /><meta name="DC.Date" content="2015/07/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK2689/" /><meta name="description" content="MYH9-related disorders (MYH9RD) are characterized by large platelets (i.e., &gt;40% of platelets &gt;3.9 μm in diameter) and thrombocytopenia (platelet count &lt;150 x 109/L), both of which are present from birth. MYH9RD is variably associated with young-adult onset of progressive sensorineural hearing loss, presenile cataract, elevation of liver enzymes, and renal disease manifesting initially as glomerular nephropathy. Before identification of the gene in which mutation is causative, MYH9, individuals with MYH9RD were diagnosed as having Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly, or Sebastian syndrome based on the combination of different clinical findings at the time of diagnosis. However, the realization that they all are due to heterozygous pathogenic variants in MYH9 and that the clinical findings often worsen throughout life as a result of late onset of non-hematologic manifestations has led the four conditions to be regarded as one disorder, now known as MYH9RD." /><meta name="og:title" content="MYH9-Related Disorders" /><meta name="og:type" content="book" /><meta name="og:description" content="MYH9-related disorders (MYH9RD) are characterized by large platelets (i.e., &gt;40% of platelets &gt;3.9 μm in diameter) and thrombocytopenia (platelet count &lt;150 x 109/L), both of which are present from birth. MYH9RD is variably associated with young-adult onset of progressive sensorineural hearing loss, presenile cataract, elevation of liver enzymes, and renal disease manifesting initially as glomerular nephropathy. Before identification of the gene in which mutation is causative, MYH9, individuals with MYH9RD were diagnosed as having Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly, or Sebastian syndrome based on the combination of different clinical findings at the time of diagnosis. However, the realization that they all are due to heterozygous pathogenic variants in MYH9 and that the clinical findings often worsen throughout life as a result of late onset of non-hematologic manifestations has led the four conditions to be regarded as one disorder, now known as MYH9RD." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK2689/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/myh9/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK2689/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D3A80E04102810000000003530138.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK2689_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK2689_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/maps/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/majeed/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK2689_"><span class="title" itemprop="name"><i>MYH9</i>-Related Disorders</span></h1><p class="contrib-group"><span itemprop="author">Anna Savoia</span>, PhD and <span itemprop="author">Alessandro Pecci</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK2689_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK2689_ai__"><div class="contrib half_rhythm"><span itemprop="author">Anna Savoia</span>, PhD<div class="affiliation small">Department of Medical Sciences<br />Institute for Maternal and Child Health - IRCCS Burlo Garofolo<br />University of Trieste<br />Trieste, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.etseirt.olrub@aiovas.anna" class="oemail">ti.etseirt.olrub@aiovas.anna</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Alessandro Pecci</span>, MD, PhD<div class="affiliation small">Department of Internal Medicine<br />IRCCS Policlinico San Matteo Foundation<br />University of Pavia<br />Pavia, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.vpinu@iccep.ordnassela" class="oemail">ti.vpinu@iccep.ordnassela</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 20, 2008</span>; Last Update: <span itemprop="dateModified">July 16, 2015</span>.</p><p><em>Estimated reading time: 28 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="myh9.Summary" itemprop="description"><h2 id="_myh9_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>MYH9</i>-related disorders (MYH9RD) are characterized by large platelets (i.e., &#x0003e;40% of platelets &#x0003e;3.9 &#x003bc;m in diameter) and thrombocytopenia (platelet count &#x0003c;150 x 10<sup>9</sup>/L), both of which are present from birth. MYH9RD is variably associated with young-adult onset of progressive sensorineural hearing loss, presenile cataract, elevation of liver enzymes, and renal disease manifesting initially as glomerular nephropathy. Before identification of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is causative, <i>MYH9</i>, individuals with MYH9RD were diagnosed as having Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly, or Sebastian syndrome based on the combination of different clinical findings at the time of diagnosis. However, the realization that they all are due to <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>MYH9</i> and that the clinical findings often worsen throughout life as a result of late onset of non-hematologic manifestations has led the four conditions to be regarded as one disorder, now known as MYH9RD.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis is established by the finding of typical MYH9 protein aggregates in neutrophils detected through immunofluorescence analysis of a peripheral blood smear and/or by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MYH9</i>. Absence of MYH9 protein aggregates in neutrophils excludes the diagnosis of MYH9RD.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> For active hemorrhage, application of local measures, desmopressin (DDAVP), and antifibrinolytic agents are used; platelet transfusion is necessary for: hemorrhages not controlled by the above treatments, life-threatening bleeding, or hemorrhages at critical sites. Hearing loss, renal complications, and cataract are managed in a standard fashion; individuals with severe/profound deafness benefit from cochlear implantation.</p><p><i>Prevention of primary manifestations:</i> Platelet transfusion, desmopressin, antifibrinolytic drugs, or eltrombopag can be used to reduce the risk of bleeding prior to surgery or invasive procedures; oral contraceptives may be effective in preventing or treating menorrhagia; regular dental care to prevent gingival bleeding.</p><p><i>Surveillance:</i> In those with bleeding episodes, blood count at least every six months to identify anemia. In all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, annual urinalysis (including 24-hour protein or protein [albumin]/creatinine ratio on a spot urine sample) and measurement of serum concentration of creatinine prior to onset of renal disease; serum liver enzyme measurements and audiometric and ophthalmologic evaluations every three years.</p><p><i>Agents/circumstances to avoid:</i> Drugs that inhibit platelet function or blood coagulation; ototoxic, nephrotoxic, and hepatotoxic drugs should be used only after careful assessment of risk versus benefit; hazardous noise and activities with high risk of injury should be avoided.</p><p><i>Evaluation of relatives at risk</i>: Screen at-risk newborns with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified; otherwise assess platelet count and size.</p><p><i>Pregnancy management</i>: Deliveries should be managed as they are in women with other forms of thrombocytopenia; a platelet count of &#x02265;50 x 10<sup>9</sup>/L is generally recommended for safe delivery.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>MYH9RD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Approximately 35% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases, half of whom have a documented <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Each offspring of an individual with MYH9RD has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant in the family is known.</p></div></div><div id="myh9.GeneReview_Scope"><h2 id="_myh9_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="myh9.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK2689/table/myh9.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myh9.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_myh9.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>MYH9</i>-Related Disorders: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_myh9.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Epstein syndrome</div></li><li class="half_rhythm"><div>Fechtner syndrome</div></li><li class="half_rhythm"><div>May-Hegglin anomaly</div></li><li class="half_rhythm"><div>Sebastian syndrome</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#myh9.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="myh9.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#myh9.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="myh9.Diagnosis"><h2 id="_myh9_Diagnosis_">Diagnosis</h2><p>The <i>MYH9</i>-related disorders (MYH9RD) were thought to be separate conditions involving <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> macrothrombocytopenia prior to the understanding of their shared molecular genetic basis.</p><div id="myh9.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>MYH9</i>-related disorders (MYH9RD) <b>should be suspected</b> in individuals with the following clinical and laboratory findings.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Manifestations of thrombocytopenia</div><ul><li class="half_rhythm"><div>Easy bruising</div></li><li class="half_rhythm"><div>Spontaneous mucocutaneous bleedings</div></li><li class="half_rhythm"><div>Excessive bleeding after hemostatic challenges (major or minor surgery, deliveries, treatment with antiplatelet drugs).</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Sensorineural hearing loss.</b> See <a href="/books/n/gene/deafness-overview/">Hereditary Hearing Loss and Deafness Overview</a> for discussion of audiologic methods to detect hearing loss.</div></li><li class="half_rhythm"><div class="half_rhythm">Glomerular nephropathy with possible renal failure (see Laboratory Findings below).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Presenile cataract</b> (occurring in early or middle life detected on slit lamp evaluation).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Family history</b> consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance.</div><div class="half_rhythm">Note: Lack of a family history of MYH9RD does not preclude the diagnosis.</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div><b>Routine blood cell counts</b> demonstrate thrombocytopenia (platelet count &#x0003c;150 x 10<sup>9</sup>/L [normal: 150 to 400 x 10<sup>9</sup>/L])</div></li><li class="half_rhythm"><div><b>Microscopic assessment</b> of a peripheral blood smear after conventional staining (such as May-Gr&#x000fc;nwald-Giemsa) demonstrates:</div><ul><li class="half_rhythm"><div class="half_rhythm">Large platelets (mean platelet diameter &#x0003e;3.7 &#x003bc;m and/or &#x0003e;40% of platelets with diameter &#x0003e;3.9 &#x000b5;m [about half a red blood cell])</div><div class="half_rhythm">Note: Electronic cell counters do not recognize the largest platelets of individuals with MYH9RD and therefore underestimate both platelet count and size in these subjects.</div></li><li class="half_rhythm"><div class="half_rhythm">D&#x000f6;hle-like bodies (faint, light blue basophilic inclusion bodies similar to the D&#x000f6;hle bodies that may be found in persons with an infection) in the cytoplasm of neutrophils</div><div class="half_rhythm">Note: D&#x000f6;hle-like bodies are present in 42%-84% of individuals with MYH9RD. They may escape detection because they are very faint and/or small [<a class="bk_pop" href="#myh9.REF.kunishima.2003.115">Kunishima et al 2003</a>, <a class="bk_pop" href="#myh9.REF.seri.2003.203">Seri et al 2003</a>].</div></li></ul></li><li class="half_rhythm"><div><b>Immunofluorescence</b> of a peripheral blood smear demonstrates typical MYH9 protein aggregates in the cytoplasm of neutrophils. These aggregates are:</div><ul><li class="half_rhythm"><div class="half_rhythm">Present from birth;</div></li><li class="half_rhythm"><div class="half_rhythm">Detectable in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#myh9.REF.kunishima.2003.115">Kunishima et al 2003</a>, <a class="bk_pop" href="#myh9.REF.savoia.2010.826">Savoia et al 2010</a>, <a class="bk_pop" href="#myh9.REF.kitamura.2013.2071">Kitamura et al 2013</a>, <a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>].</div><div class="half_rhythm">Note: In neutrophils of unaffected individuals, MYH9 protein is uniformly distributed.</div></li></ul></li><li class="half_rhythm"><div><b>Elevated liver enzymes</b> (serum alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] and occasionally serum gamma-glutamyltransferase [GGT])</div></li><li class="half_rhythm"><div><b>Urinalysis</b> demonstrating proteinuria and microhematuria</div><div>Note: Proteinuria is the earlier sign of kidney involvement</div></li><li class="half_rhythm"><div><b>Elevated serum creatinine concentration</b> (indicating progression to renal failure and risk for end-stage renal disease [ESRD])</div></li></ul></div><div id="myh9.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of MYH9RD <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with typical MYH9 protein aggregates in neutrophils detected through immunofluorescence analysis of a peripheral blood smear and/or by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MYH9</i> (see <a class="figpopup" href="/books/NBK2689/table/myh9.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figmyh9Tmoleculargenetictestingusedin" rid-ob="figobmyh9Tmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>MYH9</i> is performed first followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><p>Tiered approaches to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> numbering may vary among laboratories (see <a href="#myh9.Molecular_Genetics">Molecular Genetics</a> for exon numbering information).</p><ul><li class="half_rhythm"><div><b>Tier 1.</b> Of the 40 coding exons of <i>MYH9</i>, sequence first the five exons in which pathogenic variants are found in 84% of cases. Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants at amino acid residues 96 (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1), 702 (exon 17), 1165 (exon 27), 1424 (exon 31), and 1841 (exon 39), or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> and frameshift pathogenic variants in exon 41 have been found in 79% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (see <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">Table 2</a>).</div></li><li class="half_rhythm"><div><b>Tier 2.</b> When pathogenic variants are not detected in Tier 1 testing, the analysis is extended to exons 2, 11, 25, 26, 32, 33, 35, and 38, in which the remaining 16% of pathogenic variants have been identified [<a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>].</div></li><li class="half_rhythm"><div><b>Tier 3.</b> In individuals without an identifiable <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in Tier 1 or Tier 2 testing, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of all coding exons is performed.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>MYH9</i> and other genes of interest (see <a href="#myh9.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="myh9.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>MYH9</i>-Related Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK2689/table/myh9.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myh9.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>MYH9</i></td><td headers="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">98%&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_myh9.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="myh9.TF.1.1"><p class="no_margin">See <a href="/books/NBK2689/#myh9.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="myh9.TF.1.2"><p class="no_margin">See <a href="#myh9.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="myh9.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="myh9.TF.1.4"><p class="no_margin">Sequence analysis may be performed with a tiered approach that focuses initially on exons in which pathogenic variants are most commonly found, then on exons in which pathogenic variants have previously been identified, and finally on the remainder of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>5. </dt><dd><div id="myh9.TF.1.5"><p class="no_margin">Affected individuals: those with an aggregate distribution of MYH9 protein in neutrophils [<a class="bk_pop" href="#myh9.REF.savoia.2010.826">Savoia et al 2010</a>]</p></div></dd><dt>6. </dt><dd><div id="myh9.TF.1.6"><p class="no_margin">No <i>MYH9</i> pathogenic variants have been detected in individuals of two case series (36 and 39 subjects, respectively) with clinical findings suggestive of MYH9RD but without MYH9 protein aggregates detected through immunofluorescence [<a class="bk_pop" href="#myh9.REF.savoia.2010.826">Savoia et al 2010</a>, <a class="bk_pop" href="#myh9.REF.kitamura.2013.2071">Kitamura et al 2013</a>].</p></div></dd><dt>7. </dt><dd><div id="myh9.TF.1.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used can include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>8. </dt><dd><div id="myh9.TF.1.8"><p class="no_margin">Because a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of 1220 nucleotides leading to an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> removal of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 25 has been identified in <i>MYH9</i> [<a class="bk_pop" href="#myh9.REF.kunishima.2008b.540">Kunishima et al 2008b</a>], <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> may be appropriate in families with a strong clinical history and no identifiable <i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p></div></dd></dl></div></div></div></div></div><div id="myh9.Clinical_Characteristics"><h2 id="_myh9_Clinical_Characteristics_">Clinical Characteristics</h2><div id="myh9.Clinical_Description"><h3>Clinical Description</h3><p>In all individuals with an <i>MYH9</i>-related disorder (MYH9RD), <b>macrothrombocytopenia</b> is present at birth. Mean platelet diameter was 4.5 &#x003bc;m (95% confidence interval, 4.2-4.8) in 125 persons with MYH9RD and 2.6 &#x003bc;m (95% confidence interval, 2.4-2.7) in 55 healthy controls [<a class="bk_pop" href="#myh9.REF.noris.2014a.e4">Noris et al 2014a</a>]. Thrombocytopenia ranges from mild to severe and remains stable in an individual throughout life. Platelet counts at the lower limit of normal range have been reported in a few individuals with MYH9RD. Thus, large platelets are the only finding shared among all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>Presence and severity of spontaneous bleeding tendency correlate with the degree of thrombocytopenia. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have no spontaneous bleeding or only easy bruising. About 28% of persons with MYH9RD have spontaneous mucocutaneous bleeding, including epistaxis, gum bleeding, or menorrhagia [<a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>]. Life-threatening bleeding is rare.</p><p>The noncongenital manifestations of MYH9RD can develop anytime between infancy and adulthood. The overall annual rates per 100 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons are 1.71 for <b>sensorineural hearing loss</b>, 0.77 for <b>nephropathy</b>, and 0.57 for <b>cataract</b> [<a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>] (i.e., for example, 0.57% of individuals with MYH9RD develop cataract every year). <b>Alteration of liver enzymes</b> has been found in about 50% of individuals with MYH9RD who have been evaluated [<a class="bk_pop" href="#myh9.REF.pecci.2012a.e35986">Pecci et al 2012a</a>].</p><p><b>Sensorineural hearing loss.</b> Onset of hearing loss is distributed evenly from the first to sixth decade. Of those who develop hearing loss, 36% do so before age 20 years, 33% between ages 20 and 40 years, and 31% after age 40 years. Once diagnosed, hearing loss frequently progresses over time, although it remains stable in a minority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#myh9.REF.verver.2016.112">Verver et al 2016</a>]. Hearing loss interfering with activities of daily living is present in 90% of those individuals who have an abnormal audiometric examination [<a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>].</p><p><b>Glomerular nephropathy</b> presents with proteinuria and microhematuria. However, in MYH9RD, hematuria may result from thrombocytopenia rather than glomerular disease; therefore, proteinuria is the more reliable indicator of glomerular involvement. The mean age at onset is 27 years. Of those who develop renal disease, 72% are diagnosed before age 35 years. In most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with nephropathy, kidney damage is progressive and evolves to end-stage renal disease (ESRD). Among those with nephropathy, the overall annual rate for 100 affected persons for progression to ESRD is 6.79. After a median follow-up of 36 months, 64% of 61 affected individuals with nephropathy developed renal failure and 43% developed ESRD [<a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>].</p><p><b>Cataract.</b> The mean age of onset of cataract is 37 years, although <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> forms have been reported. In most cases, cataract is bilateral and progresses over time.</p><p><b>Elevated liver enzyme levels.</b> Elevated AST and/or ALT (possibly associated with increased GGT) usually remains stable over time. In some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, normalization of enzyme levels has been observed. Progression to impairment of liver function has not been reported in any affected individual [<a class="bk_pop" href="#myh9.REF.pecci.2012a.e35986">Pecci et al 2012a</a>, <a class="bk_pop" href="#myh9.REF.favier.2013a.1288">Favier et al 2013a</a>].</p></div><div id="myh9.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Identification of the family-specific <i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can help assess the risk of developing the noncongenital features of the disease.</p><p>Affected individuals with pathogenic variants involving the head <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the MYH9 protein have more severe thrombocytopenia compared to those with pathogenic variants affecting the tail domain. The risk of developing kidney damage, hearing loss, and cataract also depends on the specific <i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>]. See <a href="#myh9.Molecular_Genetics">Molecular Genetics</a>, <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b> for domain structure, <a href="#myh9.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b>, and <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">Table 2</a>.</p><ul><li class="half_rhythm"><div>Pathogenic variants in the codon for arginine residue 702, which is located in the short functional SH1 helix of the head <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, are associated with the most severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Individuals with Arg702 substitutions (<a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">Table 2</a>) present with severe thrombocytopenia (platelet count usually &#x0003c;50 x 10<sup>9</sup>/L) and all are expected to develop nephropathy and hearing loss before age 40 years. Moreover, nephropathy usually progresses rapidly to ESRD in these individuals.</div></li><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">p.Asp1424His</a> substitution is associated with an intermediate to high risk of developing the noncongenital manifestations of the disease. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with the p.Asp1424His variant develop kidney damage before age 60 years; all are expected to develop hearing loss within 60 years; the risk for cataracts is higher than in those with other genotypes.</div></li><li class="half_rhythm"><div>Pathogenic variants involving the residues at the interface between the SH3-like motif and the motor <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> or those resulting in substitutions of the arginine residue 1165 (see <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">Table 2</a>) are associated with a high risk for hearing loss (all are expected to develop hearing loss before age 60 years) and a low risk for nephropathy and cataract.</div></li><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">p.Asp1424Asn</a> and <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">p.Glu1841Lys</a> substitutions, as well as the <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or frameshift pathogenic variants resulting in alterations of the non-helical tailpiece (see <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">Table 2</a>), are associated with low risk of developing the noncongenital manifestations of the disease. In individuals with these pathogenic variants, thrombocytopenia usually remains the only manifestation of the disease throughout life [<a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>].</div></li></ul><p>To date, no significant <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been identified for the occurrence of liver enzyme alteration [<a class="bk_pop" href="#myh9.REF.pecci.2012a.e35986">Pecci et al 2012a</a>].</p></div><div id="myh9.Penetrance"><h3>Penetrance</h3><p>Penetrance is complete for the following <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> findings:</p><ul><li class="half_rhythm"><div>Large platelets</div></li><li class="half_rhythm"><div>MYH9 aggregates in neutrophils</div></li></ul><p>Except for a few individuals in whom platelet count was just above the conventional cut-off value for thrombocytopenia (150 x 10<sup>9</sup>/L), thrombocytopenia is a <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> manifestation of the disease.</p><p>Expressivity varies for onset and severity of sensorineural deafness, glomerular nephropathy, presenile cataract, and alterations of liver enzymes.</p></div><div id="myh9.Nomenclature"><h3>Nomenclature</h3><p>In the past, the conditions included in MYH9RD were known as</p><ul><li class="half_rhythm"><div>Epstein syndrome</div></li><li class="half_rhythm"><div>Fechtner syndrome</div></li><li class="half_rhythm"><div>May-Hegglin anomaly</div></li><li class="half_rhythm"><div>Sebastian syndrome (Sebastian platelet syndrome)</div></li></ul><p>These four disorders, characterized by thrombocytopenia with giant platelets, were classified on the basis of morphologic aspects of D&#x000f6;hle-like bodies and different combinations of the other manifestations of MYH9RD: hearing loss, glomerular nephropathy, and cataract. However, because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of a person with an <i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> often evolves over time, the diagnosis of an individual can change over time based on the appearance of a new finding or findings. Moreover, the four syndromes do not define all the possible manifestations deriving from <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>MYH9</i> pathogenic variants. Finally, members of the same family may have different phenotypes and receive different diagnoses within the spectrum of MYH9RD. For these reasons, MYH9RD has been proposed as a new nosologic entity that includes all individuals with heterozygous <i>MYH9</i> pathogenic variants independent of their neutrophil phenotype (i.e., presence of morphologic aspects of D&#x000f6;hle-like bodies) and clinical phenotype (late-onset non-hematologic manifestations) [<a class="bk_pop" href="#myh9.REF.seri.2003.203">Seri et al 2003</a>].</p></div><div id="myh9.Prevalence"><h3>Prevalence</h3><p>MYH9RD is considered a very rare disease. The <a href="http://www.registromyh9.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Italian Registry for MYH9RD</a> includes 180 Italian <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, indicating that the prevalence of the disorder in Italy is at least 3:1,000,000. Because mild forms are discovered incidentally and severe forms are often misdiagnosed as other disorders, the actual prevalence is expected to be higher.</p><p>MYH9RD has been diagnosed worldwide and there is no evidence of variation in prevalence across ethnic populations.</p></div></div><div id="myh9.Genetically_Related_Allelic_Disorde"><h2 id="_myh9_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>DFNA17, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of nonsyndromic sensorineural hearing loss that is not associated with platelet defect, is the only other <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> known to be associated with pathogenic variants in <i>MYH9</i>. A single <a href="/nuccore/NM_002473.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002473.5</a>:c.2114G&#x0003e;A (<a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">p.Arg705His</a>) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been described in two unrelated families [<a class="bk_pop" href="#myh9.REF.lalwani.2000.1121">Lalwani et al 2000</a>, <a class="bk_pop" href="#myh9.REF.hildebrand.2006.2211">Hildebrand et al 2006</a>] (see also <a href="/books/n/gene/deafness-overview/">Hereditary Hearing Loss and Deafness Overview</a>), although four additional families with the p.Arg705His pathogenic variant had macrothrombocytopenia and neutrophil MYH9 aggregates (sometimes associated with alteration of liver enzymes) along with sensorineural hearing loss [<a class="bk_pop" href="#myh9.REF.saposnik.2014.297">Saposnik et al 2014</a>, <a class="bk_pop" href="#myh9.REF.verver.2015.85">Verver et al 2015</a>].</p></div><div id="myh9.Differential_Diagnosis"><h2 id="_myh9_Differential_Diagnosis_">Differential Diagnosis</h2><p><i>MYH9</i>-related disorder (MYH9RD) should be suspected in all individuals with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> thrombocytopenia and giant platelets. It should also be considered when macrothrombocytopenia is discovered incidentally in infancy or adulthood and no previous blood counts are available to determine if the macrothrombocytopenia is congenital or acquired.</p><p>Absence of thrombocytopenia in other family members does not exclude MYH9RD because the frequency of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is high (~35% of probands) [<a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>].</p><p>The differential diagnosis of MYH9RD should take into consideration acquired and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> forms of thrombocytopenia as well as collagen IV-related nephropathies.</p><p><b>Acquired thrombocytopenia.</b> Differentiating MYH9RD from acquired forms of thrombocytopenia may be difficult and several individuals with MYH9RD have been misdiagnosed with <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> (autoimmune) thrombocytopenic purpura (ITP). This led to administration of treatments (immunosuppressive drugs and splenectomy) that are ineffective in individuals with MYH9RD. Whenever a family history of thrombocytopenia is absent or unclear, evaluation of peripheral blood slides is a simple and effective tool to distinguish individuals with MYH9RD from those with ITP, as platelets are significantly larger in persons with MYH9RD than in those with ITP. In particular, a mean platelet diameter &#x0003e;3.7 &#x000b5;m distinguishes MYH9RD from ITP with 86% <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and 87% specificity. Otherwise, a proportion of platelets with diameter &#x0003e;3.9 &#x000b5;m (about half a red blood cell) higher than 40% differentiates MYH9RD from ITP with 85% sensitivity and 87% specificity [<a class="bk_pop" href="#myh9.REF.noris.2014a.e4">Noris et al 2014a</a>].</p><p><b>Congenital thrombocytopenia</b>. The following inherited thrombocytopenias presenting with large platelets should be considered in the differential diagnosis of MYH9RD:</p><ul><li class="half_rhythm"><div><b>Bernard-Soulier syndrome (BSS)</b> (OMIM <a href="http://omim.org/entry/231200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231200</a>), an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> nonsyndromic thrombocytopenia resulting from pathogenic variants in the genes coding for platelet glycoproteins (GP) GPIb&#x003b1;, GPIb&#x003b2;, and GPIX, which together with subunit GPV constitute the von Willebrand factor receptor, GPIb/IX/V. Platelets in BSS can be as large as in MYH9RD. Bernard-Soulier syndrome is recognized by (1) failure of platelets to agglutinate in vitro after stimulation with ristocetin, and (2) absence or severe reduction of the GPIb/IX/V complex on the platelet surface detected by flow cytometry. More than 200 cases with a molecular diagnosis have been reported in the literature.</div></li><li class="half_rhythm"><div><b>Gray platelet syndrome</b> (OMIM <a href="http://omim.org/entry/139090" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">139090</a>), a very rare <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> nonsyndromic thrombocytopenia resulting from pathogenic variants in <i>NBEAL2</i>. The hallmark of Gray platelet syndrome is the finding of "pale" platelets on peripheral blood films as a result of lack of alpha granules. Electron microscopy of platelets or the finding of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>NBEAL2</i> confirms the diagnosis. Approximately 30 families have been reported in the literature.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/gata1/"><b><i>GATA1</i>-related X-linked cytopenia</b></a><b>,</b> another rare condition characterized by a mild to moderate hemolytic anemia sometimes associated with hemoglobin changes similar to <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> beta-thalassemia. An estimated fourteen families have been reported in the literature.</div></li></ul><p><a href="/books/n/gene/alport/"><b>Collagen IV-related nephropathies</b></a><b>,</b> including <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal/">autosomal</a> (dominant and recessive) forms of <a href="/books/n/gene/alport/">Alport syndrome</a> and <a href="/books/n/gene/alport/">thin basement membrane nephropathy</a>. Whereas the latter is characterized mainly by persistent microscopic hematuria, which rarely progresses to renal failure, Alport syndrome is associated with renal disease that evolves from microscopic hematuria to proteinuria, progressive renal insufficiency, and ESRD. It is also characterized by extrarenal abnormalities including progressive sensorineural hearing loss (usually present by late childhood or early adolescence), anterior lenticonus, maculopathy, corneal endothelial vesicles, and recurrent corneal erosion. Platelet defects have not been described in either Alport syndrome or thin basement membrane nephropathy. Therefore, whenever nephropathies are associated with macrothrombocytopenia, MYH9RD should be strongly considered.</p></div><div id="myh9.Management"><h2 id="_myh9_Management_">Management</h2><div id="myh9.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with an <i>MYH9</i>-related disorder (MYH9RD), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Microscopic assessment of platelet count (phase contrast microscopy by a counting chamber) to determine the degree of thrombocytopenia</div></li><li class="half_rhythm"><div>In individuals with bleeding episodes, complete blood count to evaluate for anemia</div></li><li class="half_rhythm"><div>In individuals with anemia, serum concentration of iron and ferritin level to evaluate for iron deficiency</div></li><li class="half_rhythm"><div>Audiometric evaluation</div><div>In those with severe to profound deafness, speech recognition tests</div></li><li class="half_rhythm"><div>Measurement of serum concentration of AST, ALT, and GGT</div></li><li class="half_rhythm"><div>Urinalysis, including measurement of 24-hour protein or protein (or albumin)/creatinine ratio on a spot urine sample, and measurement of serum concentration of creatinine</div></li><li class="half_rhythm"><div>In individuals with established renal involvement, testing appropriate to the severity of renal disease</div></li><li class="half_rhythm"><div>Ophthalmologic examination</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="myh9.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Bleeding tendency</b></p><ul><li class="half_rhythm"><div><b>Local measures</b> are the first-line treatment for mucocutaneous bleeding and often are sufficient to control mild or moderate bleeding. Local measures include packing or endoscopic cauterization of the bleeding site for treatment of epistaxis; suturing for treatment of accidental or surgical wounds; and compression and application of gauzes soaked in tranexamic acid for bleeding from superficial wounds. Mouthwash with tranexamic acid may control gingival bleeding.</div></li><li class="half_rhythm"><div><b>Transfusions of platelet concentrates</b> are currently used to transiently increase platelet count. Platelet transfusions have associated risks of possible alloimmunization and subsequent refractoriness to platelet infusions, infectious diseases, and acute reactions. Thus, platelet transfusions should be limited to treatment for active hemorrhages that cannot be otherwise managed, life-threatening bleedings, and/or hemorrhages at critical sites; platelet concentrates may also be used as prophylaxis prior to surgery or other major hemostatic stresses. When available, platelets from HLA-matched donors should be used to prevent or overcome alloimmunization.</div></li><li class="half_rhythm"><div><b>Eltrombopag.</b> A Phase II study in 12 persons with MYH9RD and severe thrombocytopenia demonstrated that eltrombopag, an oral drug mimicking the natural hormone that stimulates platelet production, increased platelet counts and abolished bleeding tendency in most instances [<a class="bk_pop" href="#myh9.REF.pecci.2010.5832">Pecci et al 2010</a>]. Thereafter, short-term eltrombopag courses have been successfully used in one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> adult prior to major surgery and in one child with MYH9RD and severe thrombocytopenia [<a class="bk_pop" href="#myh9.REF.pecci.2012b.1188">Pecci et al 2012b</a>, <a class="bk_pop" href="#myh9.REF.favier.2013b.e793">Favier et al 2013b</a>]. At the present time, this drug is approved in the US and Europe only for individuals with some forms of acquired thrombocytopenia.</div></li><li class="half_rhythm"><div><b>Antifibrinolytic agents.</b> Some authors recommend the systemic administration of antifibrinolytic agents, such as tranexamic or epsilon-aminocaproic acid, to treat mild or moderate mucocutaneous bleeding [<a class="bk_pop" href="#myh9.REF.boltonmaggs.2006.603">Bolton-Maggs et al 2006</a>, <a class="bk_pop" href="#myh9.REF.althaus.2009.189">Althaus &#x00026; Greinacher 2009</a>].</div></li><li class="half_rhythm"><div><b>Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP)</b> shortened bleeding time in some individuals with MYH9RD [<a class="bk_pop" href="#myh9.REF.balduini.1999.891">Balduini et al 1999</a>]. Successful surgery after prophylaxis with DDAVP has been reported [<a class="bk_pop" href="#myh9.REF.pecci.2014b.100">Pecci et al 2014b</a>]. As not all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals respond to the treatment, a test dose is recommended to identify those who will benefit from this treatment either in future bleeding episodes or in prevention of bleeding at the time of invasive procedures.</div></li></ul><p><b>Deafness.</b> A total of 11 individuals with an established diagnosis of MYH9RD and severe to profound deafness have received cochlear implantations [<a class="bk_pop" href="#myh9.REF.pecci.2014b.100">Pecci et al 2014b</a>, <a class="bk_pop" href="#myh9.REF.nabekura.2015.160">Nabekura et al 2015</a>]. Ten of them benefited from cochlear implants; nine of them obtained restoration of practically normal hearing and verbal communication abilities.</p><p><b>Glomerular nephropathy</b></p><ul><li class="half_rhythm"><div>Four <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with renal involvement had their proteinuria greatly reduced by treatment with angiotensin receptor blockers and/or angiotensin-converting enzyme inhibitors [<a class="bk_pop" href="#myh9.REF.pecci.2008.2690">Pecci et al 2008</a>]. It is premature to conclude whether this therapeutic approach prevents or delays the development of ESRD.</div></li><li class="half_rhythm"><div>Dialysis or kidney transplantation is required in individuals with ESRD.</div></li></ul><p><b>Cataracts.</b> Cataract surgery remedies clouding of the lens.</p><p><b>Elevation of liver enzymes</b> does not require any specific treatment.</p></div><div id="myh9.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Thrombocytopenia cannot be prevented; however, the risk of bleeding can be significantly reduced through education regarding drugs that affect platelet function (see <a href="#myh9.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</p><p>Affected individuals should be prepared for surgery or other invasive procedures with platelet transfusions, desmopressin, antifibrinolytic drugs, or eltrombopag according to the individual's platelet count and history of bleeding.</p><p>Oral contraceptives are often effective in preventing or controlling menorrhagia; however, oral contraceptives increase the risk of thrombosis, which has also been described in individuals with MYH9RD. Thus, the balance between risks and benefits associated with use of oral contraceptives should be considered [<a class="bk_pop" href="#myh9.REF.heller.2006.274">Heller et al 2006</a>, <a class="bk_pop" href="#myh9.REF.nishiyama.2008.228">Nishiyama et al 2008</a>, <a class="bk_pop" href="#myh9.REF.girolami.2011.474">Girolami et al 2011</a>].</p><p>Regular dental care and good oral hygiene are essential to prevent gingival bleeding.</p></div><div id="myh9.Surveillance"><h3>Surveillance</h3><p>The following evaluations should be considered at the suggested maximum intervals:</p><p><b>Every six months.</b> blood count in individuals with bleeding episodes to identify anemia; more frequent counts are appropriate in cases of recurrent profuse bleeding.</p><p><b>Every year</b></p><ul><li class="half_rhythm"><div>Urinalysis (including measurement of 24-hour protein or protein (or albumin)/creatinine ratio on spot urine sample)</div></li><li class="half_rhythm"><div>Measurement of serum concentration of creatinine</div></li><li class="half_rhythm"><div>For individuals with an established renal defect, referral to a nephrologist</div></li></ul><p><b>Every three years</b></p><ul><li class="half_rhythm"><div>Audiometric evaluation. Once hearing loss is identified, the frequency of follow-up evaluations is determined by the treating hearing specialists.</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation. Once cataract is identified, the frequency of evaluations is determined by the treating ophthalmologist.</div></li><li class="half_rhythm"><div>Measurement of serum AST, ALT and GGT</div><ul><li class="half_rhythm"><div>In individuals with alterations of liver enzymes, alternative causes of liver damage should be investigated.</div></li><li class="half_rhythm"><div>If alternative causes are excluded, the frequency of the liver enzyme measurements depends on the severity of the alteration.</div></li></ul></li></ul></div><div id="myh9.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Bleeding tendency</b></p><ul><li class="half_rhythm"><div><b>Agents.</b> Drugs that inhibit platelet function or blood coagulation:</div><ul><li class="half_rhythm"><div class="half_rhythm">Nonsteroidal anti-inflammatory drugs (NSAIDs), especially aspirin, which are strong inhibitors of platelet aggregation</div></li><li class="half_rhythm"><div class="half_rhythm">Other substances that interfere with platelet function including some antibiotics; cardiovascular, psychotropic, and oncologic drugs; drugs that affect platelet cAMP; some anesthetics; antihistamines; and radiographic contrast agents</div><div class="half_rhythm">Note: (1) Drugs that impair platelet function should be prescribed only after a careful assessment of the risks versus the benefits. (2) Physicians should try to avoid prescribing any other drugs that increase the risk of bleeding in individuals with MYH9RD. (3) Individuals with MYH9RD can develop thromboembolic events [<a class="bk_pop" href="#myh9.REF.girolami.2011.474">Girolami et al 2011</a>]. The use of antithrombotic agents (such as heparin) must be carefully balanced against the risks according to the overall clinical picture of each <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual.</div></li></ul></li><li class="half_rhythm"><div><b>Circumstances.</b> In individuals with moderate to severe thrombocytopenia, avoidance of activities at high risk of trauma (e.g., contact sports)</div></li></ul><p><b>Hearing loss</b></p><ul><li class="half_rhythm"><div><b>Agents.</b> Ototoxic drugs (e.g., aminoglycoside antibiotics, salicylates in large quantities, loop diuretics, some drugs used in chemotherapy regimens). These should be used only after a careful assessment of the risks versus the benefits.</div></li><li class="half_rhythm"><div><b>Circumstances.</b> Exposure to hazardous noise. If noise exposure cannot be avoided, use ear devices (e.g., earplugs, headphones) to attenuate intense sound.</div></li></ul><p><b>Nephropathy</b></p><ul><li class="half_rhythm"><div><b>Agents</b> that can damage renal function, including radiocontrast, antibiotics, NSAIDs, diuretics, and oncologic drugs. The balance between benefit and risk of such agents should be carefully considered, especially in individuals with established kidney involvement or with <i>MYH9</i> pathogenic variants associated with high risk for kidney damage.</div></li></ul><p><b>Cataract</b></p><ul><li class="half_rhythm"><div><b>Agents.</b> Glucocorticoids and radiation therapy, which predispose to development of cataracts</div></li></ul><p><b>Elevation of liver enzymes</b></p><ul><li class="half_rhythm"><div><b>Agents.</b> In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with liver enzyme elevation, assessment of risks versus benefits before use of potentially hepatotoxic drugs</div></li></ul></div><div id="myh9.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p><ul><li class="half_rhythm"><div>Assessing platelet count and size in a newborn at risk for MYH9RD identifies those at risk for bleeding.</div></li><li class="half_rhythm"><div>If the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to evaluate at-risk family members so that early diagnosis can inform treatment.</div></li></ul><p>See <a href="#myh9.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="myh9.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Deliveries should be managed as they are in women with other forms of thrombocytopenia (MYH9RD is not usually associated with defects of platelet function). As expected, pregnant women whose thrombocytopenia and bleeding history before pregnancy are more severe have a higher incidence of delivery-related bleeding. In general, a platelet count of &#x02265;50 x 10<sup>9</sup>/L is recommended for safe delivery. Vaginal deliveries in women with severe thrombocytopenia should be considered at increased risk for neonatal intracranial bleeding [<a class="bk_pop" href="#myh9.REF.noris.2014b.1387">Noris et al 2014b</a>].</p></div><div id="myh9.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="myh9.Genetic_Counseling"><h2 id="_myh9_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="myh9.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>MYH9</i>-related disorders (MYH9RD) are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="myh9.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Approximately 65% of individuals diagnosed with MYH9RD have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with MYH9RD may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; 35% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) &#x02013; half of whom are ascertained as having a <i>de novo</i> pathogenic variant [<a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>].</div></li></ul><p>Note: Absence of a family history of macrothrombocytopenia does not exclude the diagnosis of MYH9RD, as about 35% of probands have <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> forms resulting from <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants [<a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>].</p><ul><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, two possible explanations are a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or somatic/<a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Both germline mosaicism and <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> including the germline have been reported [<a class="bk_pop" href="#myh9.REF.kunishima.2005.360">Kunishima et al 2005</a>, <a class="bk_pop" href="#myh9.REF.kunishima.2009.260">Kunishima et al 2009</a>, <a class="bk_pop" href="#myh9.REF.kunishima.2014.885">Kunishima et al 2014</a>] (see Note).</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the family-specific pathogenic variant is known. Alternatively, when the family-specific pathogenic variant is not known or a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> resulting from potential <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> is suspected in one parent, hematologic testing (e.g., evaluation of platelet number and size, distribution of the MYH9 protein in neutrophils) should be considered.</div></li><li class="half_rhythm"><div>Apparently healthy parents must be carefully evaluated for accurate <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> in the family. Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Therefore, a negative family history cannot be confirmed until <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> and/or appropriate hematologic testing has been performed.</div></li></ul><p>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the pathogenic variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. In two families, apparently healthy parents of probands with typical MYH9RD had <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> somatic pathogenic variants with 14% or 24% of neutrophils with MYH9 aggregates but not thrombocytopenia [<a class="bk_pop" href="#myh9.REF.kunishima.2005.360">Kunishima et al 2005</a>, <a class="bk_pop" href="#myh9.REF.kunishima.2014.885">Kunishima et al 2014</a>]. In another family, the father of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> had only mild macrothrombocytopenia associated with somatic mosaicism [<a class="bk_pop" href="#myh9.REF.gresele.2013.618">Gresele at al 2013</a>].</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each offspring of an individual with MYH9RD has a 50% chance of inheriting the <i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the status of the proband's parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members may be at risk.</p></div><div id="myh9.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#myh9.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the pathogenic variant is <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="myh9.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>MYH9</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for MYH9RD are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="myh9.Resources"><h2 id="_myh9_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Society for Deaf Children (ASDC)</b></div><div>800 Florida Avenue Northeast</div><div>Suite 2047</div><div>Washington DC 20002-3695</div><div><b>Phone:</b> 800-942-2732 (Toll-free Parent Hotline); 866-895-4206 (toll free voice/TTY)</div><div><b>Fax:</b> 410-795-0965</div><div><b>Email:</b> info@deafchildren.org; asdc@deafchildren.org</div><div><a href="http://www.deafchildren.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.deafchildren.org</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Thrombocytopenia</a></div></li><li class="half_rhythm"><div><b>National Association of the Deaf (NAD)</b></div><div>8630 Fenton Street</div><div>Suite 820</div><div>Silver Spring MD 20910</div><div><b>Phone:</b> 301-587-1788; 301-587-1789 (TTY)</div><div><b>Fax:</b> 301-587-1791</div><div><b>Email:</b> nad.info@nad.org</div><div><a href="http://www.nad.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nad.org</a></div></li><li class="half_rhythm"><div><b>National Eye Institute</b></div><div>31 Center Drive</div><div>MSC 2510</div><div>Bethesda MD 20892-2510</div><div><a href="https://www.nei.nih.gov/health/cataract/cataract_facts" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Facts About Cataract</a></div></li><li class="half_rhythm"><div><b>National Kidney Foundation (NKF)</b></div><div>30 East 33rd Street</div><div>New York NY 10016</div><div><b>Phone:</b> 800-622-9010 (toll-free); 212-889-2210</div><div><b>Email:</b> info@kidney.org</div><div><a href="http://www.kidney.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidney.org</a></div></li><li class="half_rhythm"><div><b>Platelet Disorder Support Association (PDSA)</b></div><div>8751 Brecksville Road</div><div>Suite 150</div><div>Cleveland OH 44141</div><div><b>Phone:</b> 877-528-3538 (toll-free); 440-746-9003</div><div><b>Fax:</b> 844-270-1277</div><div><b>Email:</b> pdsa@pdsa.org</div><div><a href="http://www.pdsa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.pdsa.org</a></div></li><li class="half_rhythm"><div><b>Italian Registry of MYH9-Related Disease</b></div><div>Clinica Medica III IRCCS Policlinico</div><div>San Matteo Foundation </div><div>Piazzale Golgi, 2</div><div>Pavia 27100</div><div>Italy</div><div><b>Phone:</b> +39 0382.526284; +39 0382 501358</div><div><b>Fax:</b> +39 0382 526223</div><div><b>Email:</b> c.balduini@smatteo.pv.it; alessandro.pecci@unipv.it</div><div><a href="http://www.registromyh9.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.registromyh9.org</a></div></li></ul></div><div id="myh9.Molecular_Genetics"><h2 id="_myh9_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="myh9.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>MYH9-Related Disorders: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK2689/table/myh9.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myh9.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_myh9.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_myh9.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_myh9.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_myh9.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_myh9.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_myh9.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_myh9.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4627" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MYH9</i></a></td><td headers="hd_b_myh9.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4627" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q12<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_myh9.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P35579" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myosin-9</a></td><td headers="hd_b_myh9.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://hereditaryhearingloss.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary Hearing Loss Homepage (MYH9)</a><br /><a href="http://databases.lovd.nl/shared/genes/MYH9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MYH9 database</a></td><td headers="hd_b_myh9.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MYH9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MYH9</a></td><td headers="hd_b_myh9.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MYH9[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MYH9</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="myh9.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="myh9.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for MYH9-Related Disorders (<a href="/omim/155100,160775" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK2689/table/myh9.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myh9.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/155100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">155100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MACROTHROMBOCYTOPENIA AND GRANULOCYTE INCLUSIONS WITH OR WITHOUT NEPHRITIS OR SENSORINEURAL HEARING LOSS; MATINS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/160775" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">160775</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MYOSIN, HEAVY CHAIN 9, NONMUSCLE; MYH9</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>MYH9</i> consists of 41 exons. The first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> does not code for amino acids; the first methionine of the <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> is in exon 2. Exon numbering may vary among different testing laboratories. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK2689/#myh9.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> See <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">Table 2</a>.</p><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object" rid-figpopup="figmyh9Tselectedmyh9variants" rid-ob="figobmyh9Tselectedmyh9variants">Table 2</a>. Pathogenic variants occur in regions that encode the head or the tail <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the MYH9 protein (see <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>). Almost all the pathogenic variants involving the head domain are single-residue substitutions hitting one of two specific regions: (1) a group of residues clustered together to form a distinct hydrophobic interface between the SH3-like motif and the motor domain [<a class="bk_pop" href="#myh9.REF.dominguez.1998.559">Dominguez et al 1998</a>, <a class="bk_pop" href="#myh9.REF.kahr.2009.1241">Kahr et al 2009</a>], including Trp33, Val34, Asn93, Ala95 or Ser96; or (2) the residue Arg702 located in the short SH1 helix of the motor domain [<a class="bk_pop" href="#myh9.REF.eddinger.2007.c493">Eddinger &#x00026; Meer 2007</a>, <a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>, <a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>, <a class="bk_pop" href="#myh9.REF.saposnik.2014.297">Saposnik et al 2014</a>] (see <b>Normal gene product</b>). Most of the pathogenic variants involving the tail domain are either single-residue substitutions in the coiled-coil region, or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>/frameshift variants resulting in the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> and/or alteration of the C-terminal non-helical tailpiece [<a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>, <a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>, <a class="bk_pop" href="#myh9.REF.saposnik.2014.297">Saposnik et al 2014</a>]. In a few families, short <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions or duplications, usually involving the region encoding the N-terminal portion of the coiled-coil, have been identified [<a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>, <a class="bk_pop" href="#myh9.REF.pecci.2014a.236">Pecci et al 2014a</a>]. Almost 80% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have pathogenic variants involving only six residues: Ser96 or Arg702 of the head domain; Arg1165, Asp1424, Glu1841, or Arg1933 of the tail domain [<a class="bk_pop" href="#myh9.REF.balduini.2011.161">Balduini et al 2011</a>].</p><div id="myh9.T.selected_myh9_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>MYH9</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK2689/table/myh9.T.selected_myh9_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__myh9.T.selected_myh9_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_myh9.T.selected_myh9_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MYH9 Protein Domain</th><th id="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MYH9 Protein Region</th><th id="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_myh9.T.selected_myh9_variants_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2900T&#x0003e;A</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val967Glu</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_6" rowspan="15" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/225703132" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002473<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/12667788" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002464<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4876A&#x0003e;G</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile1626Val</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_1" rowspan="13" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.279C&#x0003e;G</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Head</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SH3/MD i</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn93Lys</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.287C&#x0003e;T</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Head</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SH3/MD i</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser96Leu</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2104C&#x0003e;T</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Head</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SH1 helix</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg702Cys</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2105G&#x0003e;A</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Head</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SH1 helix</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg702His</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.3493C&#x0003e;T</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1165Cys</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.3494G&#x0003e;T</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1165Leu</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4270G&#x0003e;C</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp1424His</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4270G&#x0003e;A</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp1424Asn</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4270G&#x0003e;T</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp1424Tyr</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4340A&#x0003e;T</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp1447Val</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.5521G&#x0003e;A</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coiled-coil</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu1841Lys</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.5797C&#x0003e;T</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHT</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1933Ter</td></tr><tr><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.5821delG</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tail</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHT</td><td headers="hd_h_myh9.T.selected_myh9_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp1941MetfsTer7</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">SH3/MD i = interface between the SH3-like motif and the motor <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a></p></div></dd><dt></dt><dd><div><p class="no_margin">NHT = non-helical tailpiece</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The 1960-amino acid product of <i>MYH9</i> is the heavy chain of the non-muscle myosin IIA (MYH9 protein or myosin 9) [<a class="bk_pop" href="#myh9.REF.sellers.2000.3">Sellers 2000</a>]. Non-muscle myosin IIA is a cytoplasmic myosin expressed in most cell types and tissues that participates in several key processes requiring generation of chemomechanical forces by the cytoskeleton, such as cell motility, cytokinesis, cell polarization and maintenance of cell shape [<a class="bk_pop" href="#myh9.REF.sellers.2000.3">Sellers 2000</a>, <a class="bk_pop" href="#myh9.REF.vicentemanzanares.2009.778">Vicente-Manzanares et al 2009</a>]. Like all conventional myosins, non-muscle myosin IIA is a hexameric enzyme composed of a dimer of heavy chains (MYH9 protein or myosin-9) and two pairs of light chains.</p><p>The MYH9 protein comprised two anatomically distinct domains: the N-terminal globular head <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (residues 1-835), and the C-terminal tail domain (residues 836-1960) [<a class="bk_pop" href="#myh9.REF.sellers.2000.3">Sellers 2000</a>, <a class="bk_pop" href="#myh9.REF.eddinger.2007.c493">Eddinger &#x00026; Meer 2007</a>]. The three-dimensional structure of the globular head domain consists of four subdomains connected by flexible linkers: the N-terminal SH3-like motif, the upper and the lower 50-kd subdomains, and the converter subdomain [<a class="bk_pop" href="#myh9.REF.sellers.2000.3">Sellers 2000</a>]. The two 50-kd subdomains form the so-called &#x02018;motor domain,&#x02019; as it includes the highly conserved functional regions essential for production of chemomechanical force, such as the actin-binding and the ATP-binding regions, the &#x02018;relay&#x02019; loop, and the short functional SH1 helix [<a class="bk_pop" href="#myh9.REF.dominguez.1998.559">Dominguez et al 1998</a>, <a class="bk_pop" href="#myh9.REF.sweeney.2010.539">Sweeney &#x00026; Houdusse 2010</a>, <a class="bk_pop" href="#myh9.REF.baumketner.2012.2701">Baumketner 2012</a>]. The tail domain comprises two regions: a long alpha-helical coiled-coil (residues 836-1927) that connects two MYH9 proteins to form one dimer and represents the binding site of different dimers to form functional myosin filaments, and a 34-residue (amino acids 1928-1960) C-terminal non-helical tailpiece, which is a phosphorylation site with regulatory functions [<a class="bk_pop" href="#myh9.REF.eddinger.2007.c493">Eddinger &#x00026; Meer 2007</a>, <a class="bk_pop" href="#myh9.REF.sanborn.2011.5862">Sanborn et al 2011</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Recent reports suggest that <i>MYH9</i> pathogenic variants act through different mechanisms in different cell types and that cell-specific regulation mechanisms function in MYH9RD [<a class="bk_pop" href="#myh9.REF.pecci.2005.3169">Pecci et al 2005</a>, <a class="bk_pop" href="#myh9.REF.kunishima.2008a.3015">Kunishima et al 2008a</a>]. In neutrophils the defective gene product aggregates and forms inclusion bodies that also contain the <a class="def" href="/books/n/gene/glossary/def-item/wild-type/">wild-type</a> protein [<a class="bk_pop" href="#myh9.REF.kunishima.2008a.3015">Kunishima et al 2008a</a>]. In platelets and megakaryocytes the mutated polypeptide is also expressed but at lower levels, and it does not form inclusions [<a class="bk_pop" href="#myh9.REF.deutsch.2003.529">Deutsch et al 2003</a>, <a class="bk_pop" href="#myh9.REF.kunishima.2008a.3015">Kunishima et al 2008a</a>]. Little is known about the expression of the defective protein in kidney, lens, and inner ear. Because MYH9RD is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorder and myosin consists of dimerization of two MYH9 protein molecules, the pathogenic mechanisms are likely to be associated with a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect of the pathogenic variants. This hypothesis was supported by in vitro experiments showing that mutated MYH9 proteins, expressed from any of four known pathogenic alleles, interfered with the proper assembly of wild-type myosin filaments [<a class="bk_pop" href="#myh9.REF.franke.2005.161">Franke et al 2005</a>]. However, the mechanisms leading to MYH9RD are poorly defined at both the molecular and cellular level.</p><p>In mouse megakaryocytes, phosphorylation of the myosin light chain has an important role in regulating proplatelet formation and platelet release [<a class="bk_pop" href="#myh9.REF.chen.2007.171">Chen et al 2007</a>]. Murine myosin-9 (myh9 protein) is a negative regulator of thrombopoiesis mediated by the Rho-ROCK pathway. It has been hypothesized that when the myh9 protein is defective, platelet release occurs prematurely in the marrow interstitium instead of the sinusoidal vasculature, thus leading to thrombocytopenia.</p></div><div id="myh9.References"><h2 id="_myh9_References_">References</h2><div id="myh9.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.althaus.2009.189">Althaus K, Greinacher A. MYH9-related platelet disorders. <span><span class="ref-journal">Semin Thromb Hemost. </span>2009;<span class="ref-vol">35</span>:189–203.</span> [<a href="/pubmed/19408192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19408192</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.balduini.1999.891">Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. <span><span class="ref-journal">Haematologica. </span>1999;<span class="ref-vol">84</span>:891–6.</span> [<a href="/pubmed/10509036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10509036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.balduini.2011.161">Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. <span><span class="ref-journal">Br J Haematol. </span>2011;<span class="ref-vol">154</span>:161–74.</span> [<a href="/pubmed/21542825" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21542825</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.baumketner.2012.2701">Baumketner A. The mechanism of the converter domain rotation in the recovery stroke of myosin motor protein. <span><span class="ref-journal">Proteins. </span>2012;<span class="ref-vol">80</span>:2701–10.</span> [<a href="/pmc/articles/PMC3486948/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3486948</span></a>] [<a href="/pubmed/22855405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22855405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.boltonmaggs.2006.603">Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, Minford A, Mumford AD, Parapia LA, Perry DJ, Watson SP, Wilde JT, Williams MD. UKHCDO. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. <span><span class="ref-journal">Br J Haematol. </span>2006;<span class="ref-vol">135</span>:603–33.</span> [<a href="/pubmed/17107346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17107346</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.chen.2007.171">Chen Z, Naveiras O, Balduini A, Mammoto A, Conti MA, Adelstein RS, Ingber D, Daley GQ, Shivdasani RA. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">110</span>:171–9.</span> [<a href="/pmc/articles/PMC1896110/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1896110</span></a>] [<a href="/pubmed/17392504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17392504</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.deutsch.2003.529">Deutsch S, Rideau A, Bochaton-Piallat ML, Merla G, Geinoz A, Gabbiani G, Schwede T, Matthes T, Antonarakis SE, Beris P. Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">102</span>:529–34.</span> [<a href="/pubmed/12649151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12649151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.dominguez.1998.559">Dominguez R, Freyzon Y, Trybus KM, Cohen C. Crystal structure of a vertebrate smooth muscle myosin motor domain and its complex with the essential light chain: visualization of the pre-power stroke state. <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">94</span>:559–71.</span> [<a href="/pubmed/9741621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9741621</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.eddinger.2007.c493">Eddinger TJ, Meer DP. Myosin II isoforms in smooth muscle: heterogeneity and function. <span><span class="ref-journal">Am J Physiol Cell Physiol. </span>2007;<span class="ref-vol">293</span>:C493–508.</span> [<a href="/pubmed/17475667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17475667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.favier.2013a.1288">Favier R, DiFeo A, Hezard N, Fabre M, Bedossa P, Martignetti JA. A new feature of the MYH9-related syndrome: chronic transaminase elevation. <span><span class="ref-journal">Hepatology. </span>2013a;<span class="ref-vol">57</span>:1288–9.</span> [<a href="/pubmed/22806255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22806255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.favier.2013b.e793">Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. <span><span class="ref-journal">Pediatrics. </span>2013b;<span class="ref-vol">132</span>:e793–5.</span> [<a href="/pubmed/23940247" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23940247</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.franke.2005.161">Franke JD, Dong F, Rickoll WL, Kelley MJ, Kiehart DP. Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:161–9.</span> [<a href="/pubmed/15339844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15339844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.girolami.2011.474">Girolami A, Vettore S, Bonamigo E, Fabris F. Thrombotic events in MYH9 gene-related autosomal macrothrombocytopenias (old May-Hegglin, Sebastian, Fechtner and Epstein syndromes). <span><span class="ref-journal">J Thromb Thrombolysis. </span>2011;<span class="ref-vol">32</span>:474–7.</span> [<a href="/pubmed/21842307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21842307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.gresele.2013.618">Gresele P, De Rocco D, Bury L, Fierro T, Mezzasoma AM, Pecci A, Savoia A. Apparent genotype-phenotype mismatch in a patient with MYH9-related disease: when the exception proves the rule. <span><span class="ref-journal">Thromb Haemost. </span>2013;<span class="ref-vol">110</span>:618–20.</span> [<a href="/pubmed/23925420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23925420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.heller.2006.274">Heller PG, Pecci A, Glembotsky AC, Savoia A, Negro FD, Balduini CL, Molinas FC. Unexplained recurrent venous thrombosis in a patient with MYH9-related disease. <span><span class="ref-journal">Platelets. </span>2006;<span class="ref-vol">17</span>:274–5.</span> [<a href="/pubmed/16769605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.hildebrand.2006.2211">Hildebrand MS, de Silva M, McKinlay Gardner RJ, Rose E, De Graaf CA, Bahlo M, Dahl HHM. Cochlear Implants for DFNA17 deafness. <span><span class="ref-journal">Laryngoscope. </span>2006;<span class="ref-vol">116</span>:2211–15.</span> [<a href="/pubmed/17146397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17146397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kahr.2009.1241">Kahr WH, Savoia A, Pluthero FG, Li L, Christensen H, De Rocco D, Traivaree C, Butchart SE, Curtin J, Stollar EJ, Forman-Kay JD, Blanchette VS. Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA. <span><span class="ref-journal">Thromb Haemost. </span>2009;<span class="ref-vol">102</span>:1241–50.</span> [<a href="/pubmed/19967157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19967157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kitamura.2013.2071">Kitamura K, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Furukawa K, Miyano S, Ogawa S, Kunishima S. Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders. <span><span class="ref-journal">J Thromb Haemost. </span>2013;<span class="ref-vol">11</span>:2071–3.</span> [<a href="/pubmed/24106837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24106837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kunishima.2008a.3015">Kunishima S, Hamaguchi M, Saito H. Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders. <span><span class="ref-journal">Blood. </span>2008a;<span class="ref-vol">111</span>:3015–23.</span> [<a href="/pubmed/18192507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18192507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kunishima.2008b.540">Kunishima S, Matsushita T, Hamaguchi M, Saito H. Identification and characterization of the first large deletion of the MYH9 gene associated with MYH9 disorders. <span><span class="ref-journal">Eur J Haematol. </span>2008b;<span class="ref-vol">80</span>:540–4.</span> [<a href="/pubmed/18284620" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18284620</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kunishima.2003.115">Kunishima S, Matsushita T, Kojima T, Sako M, Kimura F, Jo EK, Inoue C, Kamiya T, Saito H. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A (NMMHCA) in MYH9 disorders: association of subcellular localization with MYH9 mutations. <span><span class="ref-journal">Lab Invest. </span>2003;<span class="ref-vol">83</span>:115–22.</span> [<a href="/pubmed/12533692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12533692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kunishima.2005.360">Kunishima S, Matsushita T, Yoshihara T, Nakase Y, Yokoi K, Hamaguchi M, Saito H. First description of somatic mosaicism in MYH9 disorders. <span><span class="ref-journal">Br J Haematol. </span>2005;<span class="ref-vol">128</span>:360–5.</span> [<a href="/pubmed/15667538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15667538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kunishima.2009.260">Kunishima S, Takaki K, Ito Y, Saito H. Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents. <span><span class="ref-journal">Br J Haematol. </span>2009;<span class="ref-vol">145</span>:260–2.</span> [<a href="/pubmed/19208103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19208103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.kunishima.2014.885">Kunishima S, Kitamura K, Matsumoto T, Sekine T, Saito H. Somatic mosaicism in MYH9 disorders: the need to carefully evaluate apparently healthy parents. <span><span class="ref-journal">Br J Haematol. </span>2014;<span class="ref-vol">165</span>:885–7.</span> [<a href="/pubmed/24611568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24611568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.lalwani.2000.1121">Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN. Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">67</span>:1121–8.</span> [<a href="/pmc/articles/PMC1288554/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288554</span></a>] [<a href="/pubmed/11023810" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11023810</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.nabekura.2015.160">Nabekura T, Nagano Y, Matsuda K, Tono T. A case of cochlear implantation in a patient with Epstein syndrome. <span><span class="ref-journal">Auris Nasus Larynx. </span>2015;<span class="ref-vol">42</span>:160–2.</span> [<a href="/pubmed/25293679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25293679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.nishiyama.2008.228">Nishiyama Y, Akaishi J, Katsumata T, Katsura K, Katayama Y. Cerebral infarction in a patient with macrothrombocytopenia with leukocyte inclusions (MTCP, May-Hegglin anomaly/Sebastian syndrome). <span><span class="ref-journal">J Nippon Med Sch. </span>2008;<span class="ref-vol">75</span>:228–32.</span> [<a href="/pubmed/18781047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18781047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.noris.2014a.e4">Noris P, Biino G, Pecci A, Civaschi E, Savoia A, Seri M, Melazzini F, Loffredo G, Russo G, Bozzi V, Notarangelo LD, Gresele P, Heller PG, Pujol-Moix N, Kunishima S, Cattaneo M, Bussel J, De Candia E, Cagioni C, Ramenghi U, Barozzi S, Fabris F, Balduini CL. Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. <span><span class="ref-journal">Blood. </span>2014a;<span class="ref-vol">124</span>:e4–e10.</span> [<a href="/pmc/articles/PMC4126341/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4126341</span></a>] [<a href="/pubmed/24990887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24990887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.noris.2014b.1387">Noris P, Schlegel N, Klersy C, Heller PG, Civaschi E, Pujol-Moix N, Fabris F, Favier R, Gresele P, Latger-Cannard V, Cuker A, Nurden P, Greinacher A, Cattaneo M, De Candia E, Pecci A, Hurtaud-Roux MF, Glembotsky AC, Mu&#x000f1;iz-Diaz E, Randi ML, Trillot N, Bury L, Lecompte T, Marconi C, Savoia A, Balduini CL, Bayart S, Bauters A, Benabdallah-Guedira S, Boehlen F, Borg JY, Bottega R, Bussel J, De Rocco D, de Maistre E, Faleschini M, Falcinelli E, Ferrari S, Ferster A, Fierro T, Fleury D, Fontana P, James C, Lanza F, Le Cam Duchez V, Loffredo G, Magini P, Martin-Coignard D, Menard F, Mercier S, Mezzasoma A, Minuz P, Nichele I, Notarangelo LD, Pippucci T, Podda GM, Pouymayou C, Rigouzzo A, Royer B, Sie P, Siguret V, Trichet C, Tucci A, Saposnik B, Veneri D. European Hematology Association &#x02013; Scientific Working Group on Thrombocytopenias and Platelet Function Disorders. Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <span><span class="ref-journal">Haematologica. </span>2014b;<span class="ref-vol">99</span>:1387–94.</span> [<a href="/pmc/articles/PMC4116839/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4116839</span></a>] [<a href="/pubmed/24763399" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24763399</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.pecci.2012b.1188">Pecci A, Barozzi S, d'Amico S, Balduini CL. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation. <span><span class="ref-journal">Thromb Haemost. </span>2012b;<span class="ref-vol">107</span>:1188–9.</span> [<a href="/pubmed/22398565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22398565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.pecci.2012a.e35986">Pecci A, Biino G, Fierro T, Bozzi V, Mezzasoma A, Noris P, Ramenghi U, Loffredo G, Fabris F, Momi S, Magrini U, Pirastu M, Savoia A, Balduini C, Gresele P. Italian Registry for MYH9-releated diseases. Alteration of liver enzymes is a feature of the MYH9-related disease syndrome. <span><span class="ref-journal">PLoS One. </span>2012a;<span class="ref-vol">7</span>:e35986.</span> [<a href="/pmc/articles/PMC3338476/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3338476</span></a>] [<a href="/pubmed/22558294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22558294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.pecci.2005.3169">Pecci A, Canobbio I, Balduini A, Stefanini L, Cisterna B, Marseglia C, Noris P, Savoia A, Balduini CL, Torti M. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:3169–78.</span> [<a href="/pubmed/16162639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16162639</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.pecci.2008.2690">Pecci A, Granata A, Fiore CE, Balduini CL. Renin-angiotensin system blockade is effective in reducing proteinuria of individuals with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). <span><span class="ref-journal">Nephrol Dial Transplant. </span>2008;<span class="ref-vol">23</span>:2690–2.</span> [<a href="/pubmed/18503011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18503011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.pecci.2010.5832">Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:5832–7.</span> [<a href="/pubmed/20844233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20844233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.pecci.2014a.236">Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, Russo G, Heller PG, Loffredo G, Ballmaier M, Fabris F, Beggiato E, Kahr WH, Pujol-Moix N, Platokouki H, Van Geet C, Noris P, Yerram P, Hermans C, Gerber B, Economou M, De Groot M, Zieger B, De Candia E, Fraticelli V, Kersseboom R, Piccoli GB, Zimmermann S, Fierro T, Glembotsky AC, Vianello F, Zaninetti C, Nicchia E, G&#x000fc;thner C, Baronci C, Seri M, Knight PJ, Balduini CL, Savoia A. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. <span><span class="ref-journal">Hum Mutat. </span>2014a;<span class="ref-vol">35</span>:236–47.</span> [<a href="/pmc/articles/PMC6233870/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6233870</span></a>] [<a href="/pubmed/24186861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24186861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.pecci.2014b.100">Pecci A, Verver EJ, Schlegel N, Canzi P, Boccio CM, Platokouki H, Krause E, Benazzo M, Topsakal V, Greinacher A. Cochlear implantation is safe and effective in patients with MYH9-related disease. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2014b;<span class="ref-vol">9</span>:100.</span> [<a href="/pmc/articles/PMC4105151/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4105151</span></a>] [<a href="/pubmed/24980457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24980457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.sanborn.2011.5862">Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:5862–71.</span> [<a href="/pmc/articles/PMC3228501/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3228501</span></a>] [<a href="/pubmed/22123909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22123909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.saposnik.2014.297">Saposnik B, Binard S, Fenneteau O, Nurden A, Nurden P, Hurtaud-Roux MF, Schlegel N. French MYH9 networka. Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2014;<span class="ref-vol">2</span>:297–312.</span> [<a href="/pmc/articles/PMC4113270/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4113270</span></a>] [<a href="/pubmed/25077172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25077172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.savoia.2010.826">Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, Mumford A, Heller PG, Noris P, De Groot MR, Giani M, Freddi P, Scognamiglio F, Riondino S, Pujol-Moix N, Fabris F, Seri M, Balduini CL, Pecci A. Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. <span><span class="ref-journal">Thromb Haemost. </span>2010;<span class="ref-vol">103</span>:826–32.</span> [<a href="/pubmed/20174760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20174760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.sellers.2000.3">Sellers JR. Myosins: a diverse superfamily. <span><span class="ref-journal">Biochim Biophys Acta. </span>2000;<span class="ref-vol">1496</span>:3–22.</span> [<a href="/pubmed/10722873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10722873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.seri.2003.203">Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P, Gangarossa S, Rocca B, Gresele P, Bizzaro N, Malatesta P, Koivisto PA, Longo I, Musso R, Pecoraro C, Iolascon A, Magrini U, Rodriguez Soriano J, Renieri A, Ghiggeri GM, Ravazzolo R, Balduini CL, Savoia A. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. <span><span class="ref-journal">Medicine (Baltimore). </span>2003;<span class="ref-vol">82</span>:203–15.</span> [<a href="/pubmed/12792306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12792306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.sweeney.2010.539">Sweeney HL, Houdusse A. Structural and functional insights into the Myosin motor mechanism. <span><span class="ref-journal">Annu Rev Biophys. </span>2010;<span class="ref-vol">39</span>:539–57.</span> [<a href="/pubmed/20192767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20192767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.verver.2015.85">Verver E, Pecci A, De Rocco D, Ryh&#x000e4;nen S, Barozzi S, Kunst H, Topsakal V, Savoia A. R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17. <span><span class="ref-journal">Clin Genet. </span>2015;<span class="ref-vol">88</span>:85–9.</span> [<a href="/pubmed/24890873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24890873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.verver.2016.112">Verver EJJ, Topsakal V, Kunst HPM, Huygen PLM, Heller PG, Pujol-Moix N, Savoia A, Benazzo M, Fierro T, Grolman W, Gresele P, Pecci A. NMMHC-IIA mutation predicts severity and progression of sensorineural hearing loss in patients with <em>MYH9</em>-related disease. <span><span class="ref-journal">Ear Hear. </span>2016;<span class="ref-vol">37</span>:112–20.</span> [<a href="/pubmed/26226608" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26226608</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="myh9.REF.vicentemanzanares.2009.778">Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. <span><span class="ref-journal">Nat Rev Mol Cell Biol. </span>2009;<span class="ref-vol">10</span>:778–90.</span> [<a href="/pmc/articles/PMC2834236/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2834236</span></a>] [<a href="/pubmed/19851336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19851336</span></a>]</div></li></ul></div></div><div id="myh9.Chapter_Notes"><h2 id="_myh9_Chapter_Notes_">Chapter Notes</h2><div id="myh9.Author_History"><h3>Author History</h3><p>Carlo L Balduini, MD; University of Pavia (2008-2015)<br />Alessandro Pecci, MD, PhD (2015-present)<br />Anna Savoia, PhD (2008-present)</p></div><div id="myh9.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>16 July 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 April 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 June 2009 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically</div></li><li class="half_rhythm"><div>20 November 2008 (me) Review posted live</div></li><li class="half_rhythm"><div>9 July 2008 (as) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK2689</span><span class="label">PMID: <a href="/pubmed/20301740" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301740</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/maps/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/majeed/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK2689&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK2689/?report=reader">PubReader</a></li><li><a href="/books/NBK2689/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK2689" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK2689" style="display:none" title="Cite this Page"><div class="bk_tt">Savoia A, Pecci A. MYH9-Related Disorders. 2008 Nov 20 [Updated 2015 Jul 16]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK2689/pdf/Bookshelf_NBK2689.pdf">PDF version of this page</a> (492K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#myh9.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#myh9.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#myh9.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#myh9.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#myh9.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#myh9.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#myh9.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#myh9.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#myh9.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#myh9.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#myh9.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#myh9.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4627[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MYH9</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK2689+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1462746" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1462746" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1462746" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1462746" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301765" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> von Willebrand Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> von Willebrand Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Goodeve A, James P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301578" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Konkle BA, Huston H, Nakaya Fletcher S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301744" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301740" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301740" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0417a939a66ee2ba320a80">MYH9-Related Disorders - GeneReviews®</a><div class="ralinkpop offscreen_noflow">MYH9-Related Disorders - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:15:05-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D3A80E04102810000000003530138&amp;ncbi_session=CE8D3A80E0417A81_0851SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK2689%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK2689&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK2689/&amp;ncbi_pagename=MYH9-Related Disorders - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D3A80E0417A81_0851SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>